Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a major challenge in treating non-small cell lung cancer (NSCLC).
• Novel therapeutic strategies are needed to overcome EGFR-TKI resistance in advanced lung cancer patients.

Purpose of the Study:

• To investigate the therapeutic efficacy of co-administering afatinib with HangAmDan-B1 (HAD-B1) in gefitinib-resistant NSCLC.
• To elucidate the underlying mechanisms of action for the combined therapy.

Main Methods:

• Utilized the gefitinib-resistant NSCLC cell line HCC827-GR and a corresponding mouse model.
• Assessed cell proliferation, apoptosis, cell cycle arrest, and signaling pathway modulation (MET, ERK, mTOR).
• Conducted hematology and biochemistry tests to evaluate drug toxicity.

Main Results:

• HAD-B1 combined with afatinib significantly inhibited HCC827-GR cell proliferation and induced apoptosis more effectively than monotherapy.
• HAD-B1 monotherapy inhibited proliferation via MET amplification and reduced phosphorylation.
• The synergistic effect of afatinib and HAD-B1 led to cell cycle arrest and apoptosis through downregulation of ERK and mTOR pathways.
• HAD-B1 demonstrated a protective effect against tumor-related toxicity.

Conclusions:

• Co-administration of HAD-B1 with afatinib presents a promising therapeutic strategy for overcoming EGFR-TKI resistance in NSCLC.
• This combination therapy offers a potential new treatment option for patients with advanced lung cancer exhibiting resistance to EGFR-TKIs.